Haemonetics (NYSE:HAE) Posts Quarterly Earnings Results, Beats Estimates By $0.04 EPS

Haemonetics (NYSE:HAE) announced its quarterly earnings results on Thursday. The medical instruments supplier reported $1.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.27 by $0.04, FiscalAI reports. The firm had revenue of $338.97 million during the quarter, compared to analysts’ expectations of $331.90 million. Haemonetics had a net margin of 13.31% and a return on equity of 27.32%. The company’s revenue was down 2.7% on a year-over-year basis. During the same period in the prior year, the company posted $1.19 EPS. Haemonetics updated its FY 2026 guidance to 4.900-5.000 EPS.

Here are the key takeaways from Haemonetics’ conference call:

• Company raised full‑year guidance — reported revenue guidance tightened to a decline of ~1%–3%, organic revenue ex‑CSL raised to ~8%–10%, adjusted EPS now expected at $4.90–$5.00, and free cash flow guidance increased to $200–$220 million.
• Core product momentum — NexSys/TEG and Plasma drove outsized results (TEG adoption and a new heparinase cartridge accelerating conversions; Plasma organic growth ex‑CSL ~20% this quarter and ~22% YTD), with sustained share gains and innovation‑led pricing.
• Interventional Technologies (IVT) remains a drag — IVT revenue fell materially (down 12% Q/Q) due to esophageal cooling weakness, accelerated PFA adoption and OEM headwinds; management expects a turnaround in FY2027 but is investing now, so near‑term performance is challenged.
• Margins and cash generation strengthened — adjusted gross margin ~60%, operating‑margin guidance ~26%–27%, $74M free cash flow in the quarter (YTD $165M), cash balance up to $363M, active buybacks and the $61M Vivisure acquisition funded while keeping leverage manageable.

Haemonetics Stock Performance

Shares of HAE opened at $59.35 on Friday. The stock’s 50-day simple moving average is $76.84 and its 200 day simple moving average is $65.17. Haemonetics has a 52-week low of $47.31 and a 52-week high of $87.32. The stock has a market capitalization of $2.78 billion, a price-to-earnings ratio of 16.35, a price-to-earnings-growth ratio of 1.35 and a beta of 0.28. The company has a debt-to-equity ratio of 1.01, a quick ratio of 1.03 and a current ratio of 1.75.

Wall Street Analyst Weigh In

A number of analysts have weighed in on HAE shares. Barrington Research set a $94.00 target price on shares of Haemonetics in a research report on Friday. BTIG Research reaffirmed a “buy” rating and issued a $88.00 target price on shares of Haemonetics in a research report on Friday. Citigroup lowered their price objective on shares of Haemonetics from $88.00 to $75.00 and set a “neutral” rating on the stock in a report on Friday. Wall Street Zen raised Haemonetics from a “hold” rating to a “buy” rating in a research report on Saturday, January 10th. Finally, Raymond James Financial restated an “outperform” rating and set a $90.00 price target on shares of Haemonetics in a report on Friday, November 14th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $84.44.

Haemonetics News Summary

Here are the key news stories impacting Haemonetics this week:

• Positive Sentiment: Q3 results beat consensus: HAE reported $1.31 EPS vs. $1.27 expected and revenue of $338.97M vs. ~$331.9M, with margins improving—evidence of profitable execution. Haemonetics (HAE) Q3 Earnings and Revenues Beat Estimates
• Positive Sentiment: Company raised FY‑2026 outlook and signaled strong organic growth (management highlighted plasma and blood‑management strength and an 8%–10% organic growth outlook), which supports longer‑term revenue momentum. Haemonetics raises fiscal 2026 guidance as plasma and blood management drive 8%-10% organic growth outlook
• Positive Sentiment: Analyst support remains: BTIG reaffirmed a “buy” and a $88 price target, indicating continued analyst conviction above current levels. Benzinga coverage of BTIG rating
• Neutral Sentiment: Investor materials and transparency: the company posted its press release, slide deck and earnings‑call transcript for review—useful for digging into segment trends and guidance detail. PR Newswire: Q3 financial results available
• Neutral Sentiment: Zacks highlights HAE as a top‑ranked growth stock by style scores—an informational signal for growth‑oriented investors but not an immediate price catalyst. Haemonetics (HAE) is a Top-Ranked Growth Stock: Should You Buy?
• Negative Sentiment: Revenue weakness and mixed investor reaction: revenue fell ~2.7% YoY despite the beat, and the market reacted negatively (shares slipped after the report)—suggesting investors wanted stronger top‑line improvement or more aggressive guidance. Haemonetics Q3 Earnings & Revenues Beat, Margins Up, Stock Slips

Hedge Funds Weigh In On Haemonetics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. EverSource Wealth Advisors LLC grew its holdings in shares of Haemonetics by 2,640.0% during the second quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock worth $31,000 after purchasing an additional 396 shares in the last quarter. Caitong International Asset Management Co. Ltd grew its position in Haemonetics by 20,925.0% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 841 shares of the medical instruments supplier’s stock worth $41,000 after acquiring an additional 837 shares during the last quarter. CIBC Private Wealth Group LLC grew its holdings in shares of Haemonetics by 69.3% in the third quarter. CIBC Private Wealth Group LLC now owns 1,094 shares of the medical instruments supplier’s stock worth $53,000 after purchasing an additional 448 shares during the last quarter. Quadrant Capital Group LLC purchased a new position in shares of Haemonetics in the third quarter valued at about $76,000. Finally, Strs Ohio purchased a new position in Haemonetics during the 1st quarter valued at about $140,000. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.